KONEXElectronic Components336040

Tascom

₩4,000 0.00%2026-10-02 close

Market Cap

₩23.2B

Turnover

₩4,000

Volume

1 shares

Shares out.

5.8M

PER

—

PBR

—

EPS

—

Dividend Yield

—

PER, PBR and dividend yield are calculated from the latest confirmed results (EPS, BPS, dividend per share) and the current share price · Prices as of the 2026-10-02 close

Report overview

POCT Technology Bet Under Capital Erosion

Tascom pursues global IVD market expansion with its proprietary SimplexTAS POCT platform, but full capital erosion, persistent operating losses, and negligible KONEX market liquidity remain critical structural constraints.

1
Founded in 2014, specializing in immunochemistry, POCT, and diabetes IVD; develops, manufactures, and sells the proprietary SimplexTAS system backed by 100+ exclusive global distributors
2
Despite a 16.4% revenue decline in FY2024 (standalone basis), operating loss narrowed 62.7% and net loss contracted 58.4%, reflecting an improving gross profit mix as product strategy pivots
3
As of H1 2024, full capital erosion (total equity –KRW 220 million) and concentrated current liabilities of KRW 6.84 billion pose near-term liquidity risk
4
Resolved a KRW ~2 billion third-party allotment rights offering in December 2025 (740,740 shares at KRW 2,700/share) to fund operations and repay borrowings
5
Direct sales subsidiaries in the US, Brazil, and Germany established; pending US FDA clearance represents the single most critical medium-term growth catalyst

Business structure

Tascom is an IVD medical device company founded in 2014, with core operations spanning immunochemical diagnostics, POCT, and diabetes-related device sales alongside the in-house development, manufacturing, and distribution of the SimplexTAS platform.

SimplexTAS is described as the world's first system to use capillary blood samples directly while eliminating red blood cell interference, capable of analyzing 14+ parameters—including HbA1c, cholesterol, and creatine kinase—in approximately 13 minutes, with a development roadmap targeting more than 40 measurable biomarkers.

The product has obtained MFDS approval in Korea and, following European CE certification, has expanded distribution to clinical sites and sports teams in the Netherlands, Hungary, and Brazil, among others, now reaching 14 countries including Korea.

The company's global distribution footprint encompasses over 100 exclusive dealer networks, supplemented by direct-sales subsidiaries established through M&A and greenfield investment in the US, Brazil, and Germany.

The consumables segment—pen needles and blood glucose meters resold from iSens—accounted for approximately KRW 2.03 billion of H1 2024 revenue of KRW 3.39 billion (roughly 60%), but management has strategically wound down this line to concentrate resources on the core diagnostics device business.

Competitively, the discontinuation of Roche's 30-year-old Reflotron device has created a replacement demand pool in global clinical settings, and Tascom has pursued negotiations to position SimplexTAS as the successor product.

A long-term pipeline of stem cell-based diabetes cell therapy broadens the potential addressable market beyond diagnostics toward therapeutics.

The chronic disease POCT market benefits from structural tailwinds as aging populations and rising chronic disease prevalence drive a global paradigm shift from treatment toward early diagnosis and prevention, closely aligned with Tascom's strategic positioning.

Recent trends

For FY2024 on a standalone basis, Tascom reported a 16.4% YoY revenue decline, while its operating loss narrowed by 62.7% and net loss contracted 58.4%, reflecting gross profit improvement despite weaker top-line performance driven by the ongoing product mix shift toward higher-margin SimplexTAS.

According to press reports from mid-2024, first-half revenue stood at approximately KRW 3.39 billion, with an operating loss of approximately KRW 1.03 billion and a net loss of approximately KRW 1.06 billion.

On the balance sheet, H1 2024 data showed total equity turning negative at approximately –KRW 220 million, constituting full capital erosion, while total liabilities reached KRW 6.86 billion—of which KRW 6.84 billion was current—indicating that virtually all debt is concentrated in the near term.

Cash on hand was approximately KRW 1.72 billion, confirming that the company was unable to service obligations from internal cash flows alone.

In response, in December 2025 the company resolved to execute a KRW ~2 billion third-party allotment rights offering—issuing 740,740 shares at KRW 2,700 per share (a 0.23% discount to the reference price)—earmarking KRW ~1.4 billion for essential operating costs and KRW 600 million for debt repayment to MiCo BioMed USA and KAI-타이온유니콘조합7호.

The stock, which traded above KRW 5,000 at various points during 2025, has since retreated to KRW 2,900 as of June 7, 2026 (–3.33% vs. prior day), with a daily trading value of just KRW 222,800—reflecting KONEX's characteristically negligible liquidity.

Outlook

In the near term, restoring financial stability is the most pressing priority; the approximately KRW 2 billion raised through the rights offering is allocated entirely to immediate operating costs and debt repayment, making the escape from full capital erosion and the need for further external financing key monitoring points.

Over the medium term, US FDA clearance for SimplexTAS represents the most consequential growth milestone, as it would enable meaningful revenue leverage through the company's direct US sales entity.

The pace at which SimplexTAS organic growth can offset the revenue headwind from the consumables exit will determine the breakeven timeline. If negotiations to capture Roche Reflotron replacement demand convert into firm contracts, a meaningful demand surge across the global dealer network could follow.

On a longer-term horizon, expanding the SimplexTAS biomarker menu to over 40 assays and advancing the stem cell-based diabetes therapy pipeline into clinical trials could serve as material re-rating catalysts.

However, KONEX's structurally negligible liquidity and the absence of a clear profitability timeline keep near-term earnings visibility low.

Bull factors

Rapid Operating Loss Narrowing Signals Structural Improvement

In FY2024, Tascom's operating loss narrowed 62.7% and net loss contracted 58.4% YoY. The improvement in gross profit despite lower revenues indicates a favorable product mix shift toward the higher-margin SimplexTAS platform.

Fixed cost reductions and the phasing out of lower-margin consumables are further supporting structural margin improvement; should top-line recovery materialize, the path to breakeven could accelerate meaningfully.

Roche Reflotron Discontinuation Creates a Global Replacement Opportunity

Roche's discontinuation of the Reflotron—a 30-year market staple—has generated replacement demand across global clinical settings, and Tascom has actively pursued negotiations to position SimplexTAS as the successor.

The existing infrastructure of 100+ exclusive global distributors and direct subsidiaries in the US, Brazil, and Germany provides the supply capability needed to convert this opportunity into revenue.

With CE certification enabling sales across 14 countries, US FDA approval would unlock the largest single addressable market.

Structural POCT Market Growth Driven by Aging and Chronic Disease

The global POCT market for chronic diseases is underpinned by structural tailwinds from aging populations and rising prevalence of diabetes, hypertension, and hyperlipidemia—driving a paradigm shift from treatment to early diagnosis and prevention that directly aligns with Tascom's strategic direction.

The expanding universe of chronic disease patients worldwide represents a large and growing addressable market for SimplexTAS's multi-biomarker point-of-care capability.

The product's traction across diverse segments—domestic care homes and gyms, and international sports teams—demonstrates that the addressable customer base extends well beyond traditional clinical settings.

Bear factors

Full Capital Erosion and Concentrated Near-Term Liquidity Risk

As of H1 2024, total equity stood at approximately –KRW 220 million (full capital erosion), with current liabilities of KRW 6.84 billion representing virtually the entire debt load on a short-term basis.

With only KRW 1.72 billion in cash, the company is unable to service obligations from operating cash flows, and the KRW ~2 billion raised in December 2025 is earmarked entirely for immediate operating and repayment needs.

If operating losses persist, a going-concern qualification from the auditor cannot be ruled out, and meaningful balance sheet rehabilitation is likely to require considerable time.

Persistent Revenue Decline and Uncertain Breakeven Timeline

Revenue fell 16.4% YoY in FY2024, and the strategic wind-down of consumables—which accounted for approximately 60% of H1 2024 revenue—will likely exert further near-term top-line pressure.

Whether SimplexTAS organic growth can adequately offset this headwind remains uncertain, and no clear breakeven timeline has been publicly communicated. With earnings visibility structurally low, investment analysis is necessarily reliant on qualitative assessments of technology potential versus financial risk.

Structural Illiquidity on the KONEX Market

As of the reference date (June 7, 2026), daily trading value amounted to just KRW 222,800 and market capitalization is negligible, making conventional entry and exit for most investors practically impossible.

This absence of market liquidity distorts price discovery and amplifies price volatility in response to even marginal changes in near-term supply and demand.

Without structural catalysts such as a transfer listing to KOSDAQ or meaningful institutional sponsorship, illiquidity is likely to remain a persistent feature of the stock.

Risk factors

Regulatory Risk

US FDA clearance is the most critical prerequisite for scaling global revenues, yet specific timelines and regulatory outcomes have not been publicly disclosed, leaving material uncertainty. Delays or rejections in the approval process could set back the company's direct US sales strategy significantly.

Changes in domestic and international medical device regulatory frameworks could also affect the maintenance of existing product approvals and the launch schedule of new biomarker assays.

Balance Sheet Deterioration Risk

Continued operating losses under conditions of full capital erosion could result in failure to meet KONEX listing maintenance standards or a going-concern qualification from the company's auditor. Additional rights offerings needed to fund operations would impose further dilution on existing shareholders.

Given the concentration of current liabilities, any disruption to debt repayment schedules could expose the company to default risk.

Competitive and Macro Risk

The global IVD market is dominated by major multinationals—Roche, Abbott, and Siemens—making independent market share gains structurally challenging for small specialized players. In the POCT segment, intensification of competition on technology capability or pricing could erode SimplexTAS's differentiation over time.

Broader macroeconomic headwinds—including global economic slowdown and foreign exchange volatility—could impair international revenue and the sustainability of the global dealer network.

Overall view

Tascom possesses a differentiated technology platform (SimplexTAS) targeting the structurally growing chronic disease POCT market, and the material narrowing of operating losses in FY2024 is an early constructive signal of structural improvement.

However, full capital erosion, concentrated short-term liabilities, a declining revenue base, and negligible KONEX liquidity collectively limit conventional investment access in a fundamental way.

The KRW ~2 billion rights offering executed in late 2025/early 2026 provides a near-term liquidity bridge but falls short of fully rehabilitating the balance sheet; meaningful SimplexTAS revenue growth is a necessary precondition for genuine financial recovery.

US FDA clearance and the conversion of Roche Reflotron replacement negotiations into binding contracts represent the most critical medium-term inflection points, yet both remain on an unclear timeline.

The stem cell-based diabetes therapy pipeline carries long-term re-rating optionality, but the clinical development path and funding capability remain unverified.

In sum, Tascom is a high-risk micro-cap where technological optionality and financial fragility coexist in a challenging balance, warranting a cautious observational stance until concrete evidence of profit trajectory and improved liquidity conditions materializes.

Sources

Korea Exchange (KRX) — Prices · Market Cap · Volume
FSS electronic disclosure system (DART) — Financial statements · Dividend filings

Show 6 more articles and sources

Report written 2026-06-08 · Data as of 2026-06-05

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.